(Q50861849)
Statements
1 reference
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. (English)
1 reference
Konstanze Döhner
1 reference
Hartmut Döhner
1 reference
Thorsten Zenz
1 reference
Michael Hallek
1 reference
Stephan Stilgenbauer
1 reference
Andrea Schnaiter
1 reference
Peter Paschka
1 reference
Marianna Rossi
1 reference
Andreas Bühler
1 reference
Dirk Winkler
1 reference
Mario Cazzola
1 reference
Jennifer Edelmann
1 reference
Sabrina Kless
1 reference
Silja Mack
1 reference
Raymonde Busch
1 reference
2 July 2013
1 reference
1 reference
122
1 reference
7
1 reference
1266-1270
1 reference
Identifiers
1 reference